4Wittes, R E, From research to approved treatment: overcoming the obstacles [ J ]. Semin-Henato, 1998,25 (3Suppl) :38.
5Wenzel L B, Huang H Q,Armstrong D K,et al. Baseline quality of life (QOL) as a predictor of tolerance to fntraperitoneal ( IP ) chemotherapy for advanced epithelial ovarian cancer ( EOC ) : A Gynecologic Oncology Group (GOG) study [ J]. J Clinoneology, 2006,24(18S) :5007.
6Kinoshitad J, Kitamura K, Kabashima A, et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer [ J ]. Breast Cancer Res Treat, 2001, 66 ( 2 ) : 159.